Incyte (INCY) Shares Outstanding (Weighted Average) (2010 - 2026)
Incyte posted quarterly Shares Outstanding (Weighted Average) of $199.3 million for Q1 2026, up 2.91% year-on-year from $193.7 million in Q1 2025, and up 2.12% on a QoQ basis from $195.2 million in Q4 2025.
Incyte (INCY) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $199.3 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 2.91% year-over-year to $199.3 million; the trailing twelve-month figure through Mar 2026 stood at $199.3 million (up 2.91% YoY), and the FY2025 full-year result was $195.2 million, down 5.75% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $199.3 million, up from $195.2 million in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $224.5 million in Q1 2024 and bottomed at $193.7 million in Q1 2025.
- The 5-year median for Shares Outstanding (Weighted Average) is $221.3 million (2022), against an average of $212.9 million.
- The widest annual swing landed in 2025, when Shares Outstanding (Weighted Average) decreased 13.71%; it then climbed 2.91% in 2026.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $222.0 million in 2022, then rose by 0.73% to $223.6 million in 2023, then declined by 7.39% to $207.1 million in 2024, then slipped by 5.75% to $195.2 million in 2025, then increased by 2.12% to $199.3 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $199.3 million (Q1 2026), $195.2 million (Q4 2025), and $195.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn | 199.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 199.34 Mn |
| Dec 31, 2025 | 195.20 Mn |
| Sep 30, 2025 | 195.67 Mn |
| Jun 30, 2025 | 194.00 Mn |
| Mar 31, 2025 | 193.71 Mn |
| Dec 31, 2024 | 207.11 Mn |
| Sep 30, 2024 | 211.76 Mn |
| Jun 30, 2024 | 218.18 Mn |
| Mar 31, 2024 | 224.48 Mn |
| Dec 31, 2023 | 223.63 Mn |
| Sep 30, 2023 | 223.43 Mn |
| Jun 30, 2023 | 223.10 Mn |
| Mar 31, 2023 | 222.96 Mn |
| Dec 31, 2022 | 222.00 Mn |
| Sep 30, 2022 | 222.42 Mn |
| Jun 30, 2022 | 221.49 Mn |
| Mar 31, 2022 | 221.33 Mn |
| Dec 31, 2021 | 220.43 Mn |
| Sep 30, 2021 | 220.24 Mn |
| Jun 30, 2021 | 219.94 Mn |
| Mar 31, 2021 | 219.80 Mn |
| Dec 31, 2020 | 218.07 Mn |
| Sep 30, 2020 | 217.68 Mn |
| Jun 30, 2020 | 217.55 Mn |
| Mar 31, 2020 | 216.72 Mn |
| Dec 31, 2019 | 214.91 Mn |
| Sep 30, 2019 | 215.20 Mn |
| Jun 30, 2019 | 214.62 Mn |
| Mar 31, 2019 | 214.07 Mn |
| Dec 31, 2018 | 212.38 Mn |
| Sep 30, 2018 | 212.63 Mn |
| Jun 30, 2018 | 212.21 Mn |
| Mar 31, 2018 | 211.68 Mn |
| Dec 31, 2017 | 204.58 Mn |
| Sep 30, 2017 | 206.80 Mn |
| Jun 30, 2017 | 205.14 Mn |
| Mar 31, 2017 | 195.26 Mn |
| Dec 31, 2016 | 187.87 Mn |
| Sep 30, 2016 | 188.03 Mn |
| Jun 30, 2016 | 187.68 Mn |
| Mar 31, 2016 | 187.18 Mn |
| Dec 31, 2015 | 179.60 Mn |
| Sep 30, 2015 | 181.39 Mn |
| Jun 30, 2015 | 178.68 Mn |
| Mar 31, 2015 | 172.07 Mn |
| Dec 31, 2014 | 167.95 Mn |
| Sep 30, 2014 | 168.59 Mn |
| Jun 30, 2014 | 167.91 Mn |
| Mar 31, 2014 | 165.36 Mn |
| Dec 31, 2013 | 148.40 Mn |
| Sep 30, 2013 | 155.07 Mn |
| Jun 30, 2013 | 142.28 Mn |
| Mar 31, 2013 | 134.35 Mn |
| Dec 31, 2012 | 129.75 Mn |
| Sep 30, 2012 | 130.85 Mn |
| Jun 30, 2012 | 129.22 Mn |
| Mar 31, 2012 | 127.20 Mn |
| Dec 31, 2011 | 125.36 Mn |
| Sep 30, 2011 | 126.26 Mn |
| Jun 30, 2011 | 125.33 Mn |
| Mar 31, 2011 | 123.47 Mn |
| Dec 31, 2010 | 121.63 Mn |
| Sep 30, 2010 | 122.19 Mn |
| Jun 30, 2010 | 121.63 Mn |
| Mar 31, 2010 | 119.73 Mn |